Histone modifying enzymes: novel disease biomarkers and assay development

被引:25
作者
Ma, Fei [1 ]
Zhang, Chun-yang [1 ]
机构
[1] Shandong Normal Univ, Collaborat Innovat Ctr Functionalized Probes Chem, Shandong Prov Key Lab Clean Prod Fine Chem, Coll Chem Chem Engn & Mat Sci,Minist Educ,Key Lab, Jinan, Peoples R China
基金
中国国家自然科学基金;
关键词
Assay development; cancer; disease biomarker; histone modifying enzyme; histone post-transcriptional modification; RUBINSTEIN-TAYBI-SYNDROME; AURORA-B KINASE; DEACETYLASE INHIBITORS; CHROMATIN-STRUCTURE; ANDROGEN-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; THERAPEUTIC STRATEGY; PROSTATE-CANCER; BREAST-CANCER; GENE;
D O I
10.1586/14737159.2016.1135057
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Histones are the chief components of chromatin. When being catalyzed by a series of histone modifying enzymes, histones may undergo various post-translational modifications such as acetylation, methylation, phosphorylation, ubiquitylation and SUMOylation. The dysregulation of histone modifying enzymes will alter the histone post-modification patterns and cause diverse diseases including cancers. Consequently, the histone modifying enzymes have emerged as the promising biomarkers for disease diagnosis and prognosis. In this review, we summarize the recent researches about the histone modifying enzymes as the disease biomarkers, and highlight the development of methods for histone modifying enzyme assays.
引用
收藏
页码:297 / 306
页数:10
相关论文
共 102 条
[71]   Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond [J].
Quintas-Cardama, Alfonso ;
Kantarjian, Hagop ;
Cortes, Jorge ;
Verstovsek, Srdan .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (02) :127-140
[72]   Regulation of chromatin structure by site-specific histone H3 methyltransferases [J].
Rea, S ;
Eisenhaber, F ;
O'Carroll, N ;
Strahl, BD ;
Sun, ZW ;
Schmid, M ;
Opravil, S ;
Mechtler, K ;
Ponting, CP ;
Allis, CD ;
Jenuwein, T .
NATURE, 2000, 406 (6796) :593-599
[73]   Genetic heterogeneity in Rubinstein-Taybi syndrome:: Mutations in both the CBP and EP300 genes cause disease [J].
Roelfsema, JH ;
White, SJ ;
Ariyürek, Y ;
Bartholdi, D ;
Niedrist, D ;
Papadia, F ;
Bacino, CA ;
den Dunnen, JT ;
van Ommen, GJB ;
Breuning, MH ;
Hennekam, RC ;
Peters, DJM .
AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 76 (04) :572-580
[74]   ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease [J].
Ryu, Hoon ;
Lee, Junghee ;
Hagerty, Sean W. ;
Soh, Byoung Yul ;
McAlpin, Sara E. ;
Cormier, Kerry A. ;
Smith, Karen M. ;
Ferrante, Robert J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (50) :19176-19181
[75]   Histone lysine demethylases: emerging roles in development, physiology and disease [J].
Shi, Yang .
NATURE REVIEWS GENETICS, 2007, 8 (11) :829-833
[76]   Histone demethylation mediated by the nuclear arnine oxidase homolog LSD1 [J].
Shi, YJ ;
Lan, F ;
Matson, C ;
Mulligan, P ;
Whetstine, JR ;
Cole, PA ;
Casero, RA ;
Shi, Y .
CELL, 2004, 119 (07) :941-953
[77]   Histone H4-K16 acetylation controls chromatin structure and protein interactions [J].
Shogren-Knaak, M ;
Ishii, H ;
Sun, JM ;
Pazin, MJ ;
Davie, JR ;
Peterson, CL .
SCIENCE, 2006, 311 (5762) :844-847
[78]   Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation [J].
Sorrentino, R ;
Libertini, S ;
Pallante, PL ;
Troncone, G ;
Palombini, L ;
Bavetsias, V ;
Spalletti-Cernia, D ;
Laccetti, P ;
Linardopoulos, S ;
Chieffi, P ;
Fusco, A ;
Portella, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (02) :928-935
[79]   Steroid receptor coactivator-1 is a histone acetyltransferase [J].
Spencer, TE ;
Jenster, G ;
Burcin, MM ;
Allis, CD ;
Zhou, JX ;
Mizzen, CA ;
McKenna, NJ ;
Onate, SA ;
Tsai, SY ;
Tsai, MJ ;
OMalley, BW .
NATURE, 1997, 389 (6647) :194-198
[80]   The language of covalent histone modifications [J].
Strahl, BD ;
Allis, CD .
NATURE, 2000, 403 (6765) :41-45